Available Technologies

Browse Penn-owned technologies available for licensing.

HOME SEARCH RSS FEED

ANTIBODY-LIKE THERAPEUTIC PLATFORM WITH EFFECTOR FUNCTION

Description:

While antibody therapeutics have proven to be successful in recent years, they are not without drawbacks. The large size of antibodies can prevent their effective use against certain cancers, as well as prevent them from crossing the blood-brain barrier. Additionally, many antibodies require post-translational modifications and must be produced in eukaryotic cells, decreasing their yield and increasing costs of production. To overcome the existing drawbacks of current antibody and non-antibody synthetic protein approaches, the inventors have generated a novel, small recombinant antigen-binding protein platform produced in e. coli. 

S22Fc antibody-like protein is a representative example of this platform that has been engineered to bind HER2, HER3, EGFR and interact with the Fc receptor on immune effector cells to enhance the activity of the immune system; S22Fc is effective at treating anti-EGFR and anti-HER2 antibody resistant tumors with demonstrated in vivo POC.

IP Status:
Pending US rights
Pending CN rights

References:
Greene, M. I., et al. (2012). Antibody-like proteins for therapeutic and diagnostic use. WO 2012122378.

 

Docket # X5822


Patent Information:
For Information, Contact:
Viviane Martin
Director, PSOM Licensing Group
University of Pennsylvania
martinv@upenn.edu
Inventors:
Mark Greene
Keywords:
Antibody
Therapeutics